HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.

AbstractBACKGROUND:
We previously reported that the functional mutation of Toll-like receptor 4 (TLR4) in C3H/HeJ mice subjected to myocardial ischemia-reperfusion (MI/R) injury resulted in an attenuation of myocardial infarction size. To investigate the ligand-activating TLR4 during MI/R injury, we evaluated the effect of eritoran, a specific TLR4 antagonist, on MI/R injury, with the goal of defining better therapeutic options for MI/R injury.
METHODS AND RESULTS:
C57BL/6 mice received eritoran (5 mg/kg) intravenously 10 minutes before 30 minutes of in situ of transient occlusion of the left anterior descending artery, followed by 120 minutes of reperfusion. Infarct size was measured using triphenyltetrazoliumchloride staining. A c-Jun NH(2)-terminal kinase (JNK) activation was determined by Western blotting, nuclear factor (NF)-kappaB activity was detected by gel-shift assay, and cytokine expression was measured by ribonuclease protection assay. Mice treated with eritoran developed significantly smaller infarcts when compared with mice treated with vehicle alone (21.0+/-6.4% versus 30.9+/-13.9%; P=0.041). Eritoran pretreatment resulted in a reduction in JNK phosphorylation (eritoran versus vehicle: 3.98+/-0.81 versus 7.01+/-2.21-fold increase; P=0.020), less nuclear NF-kappaB translocation (2.70+/-0.35 versus 7.75+/-0.60-fold increase; P=0.00007), and a decrease in cytokine expression (P<0.05).
CONCLUSIONS:
We conclude that inhibition of TLR4 with eritoran in an in situ murine model significantly reduces MI/R injury and markers of an inflammatory response.
AuthorsAkira Shimamoto, Albert J Chong, Masaki Yada, Shin Shomura, Hiroo Takayama, Ani J Fleisig, Matthew L Agnew, Craig R Hampton, Christine L Rothnie, Denise J Spring, Timothy H Pohlman, Hideto Shimpo, Edward D Verrier
JournalCirculation (Circulation) Vol. 114 Issue 1 Suppl Pg. I270-4 (Jul 04 2006) ISSN: 1524-4539 [Electronic] United States
PMID16820585 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Cytokines
  • Disaccharides
  • NF-kappa B
  • Sugar Phosphates
  • Tlr4 protein, mouse
  • Toll-Like Receptor 4
  • eritoran
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases
Topics
  • Animals
  • Biomarkers
  • Cytokines (biosynthesis, genetics)
  • Disaccharides (pharmacology, therapeutic use)
  • Drug Evaluation, Preclinical
  • Enzyme Activation (drug effects)
  • Inflammation
  • JNK Mitogen-Activated Protein Kinases (metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinases (metabolism)
  • Myocardial Infarction (complications, pathology)
  • Myocardial Reperfusion Injury (prevention & control)
  • NF-kappa B (metabolism)
  • Phosphorylation (drug effects)
  • Protein Processing, Post-Translational (drug effects)
  • Sugar Phosphates (pharmacology, therapeutic use)
  • Toll-Like Receptor 4 (antagonists & inhibitors, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: